Abstract: To achieve high accuracy and high processing speed, a time series data evaluation device is equipped with a probability calculation unit 201 that calculates the probability p(i) that ?t?Ai; a division entropy calculation unit 202 that calculates division entropy using the measure in the subdivision interval by setting a subdivision section Bi (i=1, 2, . . . , M×Q) by further dividing the divided section Ai (i=1, 2, . . . , M) into Q equal parts; and a summation calculation unit 203 that performs a summation calculation of the divided interval range regarding the multiplication of the probability p(i) and the division entropy.

Abstract: A prophylactic or therapeutic agent for a myopathy, including a miR-33b inhibitor, preferably an antisense oligonucleotide against miR-33b, as an effective component.

Abstract: A solid oxide electrochemical cell includes a solid hydrogen electrode, a solid electrolyte membrane, and a solid oxygen electrode. The solid hydrogen electrode includes, in a first surface thereof, a plurality of first raised portions raised in a direction toward the solid electrolyte membrane and first intermediate portions each located between two adjacent ones of the first raised portions. The solid electrolyte membrane includes second raised portions stacked on the first raised portions and second intermediate portions stacked on the first intermediate portions. The solid oxygen electrode includes third raised portions stacked on the second raised portions and third intermediate portions stacked on the second intermediate portions. The first raised portions have a pitch of 70 to 110 ?m. The second intermediate portions are in contact with the third intermediate portions without a gap therebetween.

Abstract: The present disclosure provides a composition for ameliorating a skin tissue abnormality comprising a compound of formula (I) or an ester, oxide, pharmaceutically acceptable salt or solvate thereof.

Abstract: A superconducting rotating machine includes a stator that includes a cylindrical stator iron core and a stator winding that is toroidally wound around the stator iron core and formed of a superconducting material, and generates a rotating magnetic field, an inner rotor rotatably held at an inner circumferential side of the stator, and an outer rotor rotatably held at an outer circumferential side of the stator. The inner and outer rotors each include at least one rotor winding selected from a superconducting squirrel cage winding including a single or a plurality of rotor bars and end rings that are formed of a superconducting material, and a normal conducting squirrel cage winding including a single or a plurality of rotor bars and end rings that are formed of a normal conducting material, and a rotor iron core including a plurality of slots that accommodate respective rotor bars of the rotor winding.

Abstract: A pharmaceutical composition for genetic diseases caused by an aberrant splicing regulation is provided. Provided are a pharmaceutical composition for preventing, ameliorating, suppressing progression of, and/or treating the genetic diseases caused by an aberrant splicing regulation, the pharmaceutical composition containing, as an active ingredient, a compound capable of suppressing an aberrant splicing regulation that contributes to the development or progression of genetic diseases caused by an aberrant splicing regulation, and a method for preventing, ameliorating, suppressing progression of, and/or treating the genetic diseases using a compound capable of suppressing an aberrant splicing regulation that contributes to the development or progression of genetic diseases caused by an aberrant splicing regulation.

Abstract: A first open/close valve (12a), a drip chamber (14), and a variable valve (17) are provided in this order on a first flow path (10a) from a first connector (11a) side toward a downstream connector (19) side. A second flow path (10b), on which a second open/close valve (12b) is provided, is connected to a section of the first flow path between the first open/close valve and the drip chamber. A priming method includes a first step of causing the first liquid to flow from a first container (20a) into the first flow path and priming the first flow path using the first liquid, and a second step of causing the second liquid to flow from a second container (20b) into the second flow path and priming the second flow path using the second liquid. In the second step, the second liquid moves air that has been present in the second flow path toward the first container (20a).

Abstract: The present invention provides a cardiomyocyte maturation promoter. The present invention provides a cardiomyocyte maturation promoter comprising one or more compounds selected from 2-methoxy-5-((Z)-2-(3,4,5-trimethoxyphenyl)vinyl)phenol, (1-ethyl-1H-benzotriazol-5-yl)methyl (2-(2-methoxy-4-methylphenyl)-4-methyl-1,3-thiazol-5-yl)carbamate, (2?beta)-22-oxovincaleukoblastine, 2-(2-(4-chlorophenyl)ethyl)-6-(2-furyl)-3H-imidazo[4,5-b]pyridine, 4,5-anhydro-1,2-dideoxy-4-methyl-2-((N-(morpholin-4-ylacetyl)-L-alanyl-O-methyl-L-tyrosyl)amino)-1-phenyl-L-threo-pent-3-ulose, 3-(3-methoxyphenyl)-N7,N7-dimethylisoquinoline-1,7-diamine, methyl 4-(2-benzylbenzoyl)-2,5-dimethyl-1H-pyrrole-3-carboxylate, 2?-(4-aminophenyl)-1H,1?H-2,5?-bibenzimidazol-5-amine, and salts thereof.

Abstract: The disclosure provides a method of freezing an aggregate of pluripotent stem cell-derived cardiomyocytes, comprising: (i) immersing an aggregate of pluripotent stem cell-derived cardiomyocytes in a cryoprotective solution; and (ii) freezing the aggregate immersed in the cryoprotective solution. The disclosure also provides a frozen aggregate of pluripotent stem cell-derived cardiomyocytes frozen by the method.

Abstract: A bonding layer evaluation system includes an elastic wave generation device configured to generate an elastic wave from a sample including a bonding layer; an elastic wave reflection body configured to reflect the elastic wave generated from the sample; a sample installation unit provided between the elastic wave generation device and the elastic wave reflection body; an elastic wave detection device disposed in a direction in which the elastic wave is reflected by the elastic wave reflection body, and configured to detect the reflected elastic wave; and a control device configured to evaluate a parameter related to the bonding layer. The control device evaluates the parameter related to the bonding layer by comparing the actual value of the elastic wave detected by the elastic wave detection device with a theoretical value of the elastic wave calculated based on a theoretical model related to the sample.

Abstract: A medical image processing apparatus according to the present embodiment includes processing circuitry. The processing circuitry receives an instruction to move a slice position when a three-dimensional medical image including a plurality of slice images of a subject is displayed. The processing circuitry controls a display to display a slice image at a destination slice position as a first image when the received instruction is an instruction to move the slice position by less than a predetermined interval, and controls the display to display a second image reflecting information on a plurality of slice images including the slice image at the destination slice position when the received instruction is an instruction to move the slice position by more than the predetermined interval.

Abstract: The inventors have found that the compounds of formula (I) protect cardiomyocytes. Accordingly, the disclosure provides a pharmaceutical composition for protecting a cardiomyocyte comprising a compound of formula (I) or an ester, oxide, pharmaceutically acceptable salt or solvate thereof. The pharmaceutical composition may be used for treating or preventing a disease associated with cardiomyocyte death, such as myocardial infarction, chronic heart failure, hypertensive heart failure, or dilated cardiomyopathy, especially for treating myocardial infarction.

Abstract: The invention provides an in vitro method of improving the efficiency of establishment of induced pluripotent stem (iPS) cells. The method comprises contacting an isolated somatic cell being reprogrammed into an iPS cell with an inhibitor of p53 function. The invention also provides an in vitro method of producing iPS cells. The method comprises bringing (a) nuclear reprogramming substances or nucleic acids encoding the nuclear reprogramming substances and (b) an inhibitor of p53 function into contact with a somatic cell.

Abstract: A method efficiently produces cytotoxic T lymphocytes having intrinsic properties of lymphocytes of the acquired immune system suitable for cellular immunotherapy. The method includes culturing CD4/CD8 double-positive T cells in a medium containing IL-7 and a T-cell receptor activator, to induce CD8?+?+ cytotoxic T lymphocytes.

Abstract: The compound of the present invention includes a structure having: a chelating part capable of coordinating with a radioactive metal ion; a first atomic group containing an albumin-binding part; and a second atomic group containing a PSMA molecule-binding part, wherein the first atomic group and the second atomic group are bonded with each other through the chelating part, or the chelating part is bonded from between the first atomic group and the second atomic group so that it makes a branch. The present invention also provides: a radiolabeled compound in which the compound is coordinated with a radioactive metal ion; and a method for manufacturing a radiolabeled compound.

Abstract: Disclosed is a eutectic mixture containing a first component and a second component as main components. The first component is a quaternary ammonium salt, and the second component is an aminocarboxylic acid and/or a derivative thereof, the aminocarboxylic acid having a —COOH group and an —NH— group in the same molecule. The eutectic mixture has a melting point, Tm, which is lower than the melting point of the first component, T1, and which is lower than the melting point of the second component, T2. The eutectic mixture is in a homogeneous liquid state at a temperature higher than the melting point, Tm. Disclosed is a liquid composition containing a third component dissolving in the eutectic mixture. The third component contains one or two or more selected from cellulose, hemicellulose, and lignin.

Abstract: Provided is a crystalline oxide film including an oxide of germanium, an area percentage of abnormal grains determined by surface SEM observation being 3% or less.

Abstract: Provided are a reagent for transparentizing a carbohydrate- or protein-containing material, the reagent including a compound selected from the group consisting of a benzene carboxylic acid compound, a hydroxybenzene compound, a benzene sulfonic acid compound, a homosulfamine compound, and a benzenesulfohydroxamic acid compound; and a method for transparentizing said material, including processing the carbohydrate- or protein-containing material in said reagent.

Abstract: The present invention provides peptides, salts thereof, peptide conjugates, and salts thereof having an anxiolytic-like effect, for example a peptide comprising any amino acid sequence selected from (i) an amino acid sequence SYLPPLTT (SEQ ID NO: 1), (ii) an amino acid sequence YHIEPV (SEQ ID NO: 2), (iii) an amino acid sequence YLLVK (SEQ ID NO: 3), (iv) an amino acid sequence SYLPPLT (SEQ ID NO: 4), (v) an amino acid sequence FLLVK (SEQ ID) NO. 5), and (vi) an amino acid sequence WLLVK (SEQ ID NO: 6).

Abstract: A photonic crystal surface-emitting laser includes a light emitting region from which light is emitted in a direction crossing an in-plane direction, and a current blocking region that is adjacent to the light emitting region in the in-plane direction and in which current is less likely to flow than in the light emitting region. The light emitting region and the current blocking region each include a photonic crystal layer. The photonic crystal layer has a first region and second regions periodically arranged in the first region. A refractive index of each of the second regions is different from that of the first region. The light emitting region includes a first semiconductor layer, an active layer, and a second semiconductor layer. The first semiconductor layer, the active layer, and the second semiconductor layer are sequentially stacked on top of one another in an emission direction of the light.